Shares of WuXi AppTec (WUXI APPTEC) plummeted by 5.36% on Monday, as the company announced that it is assessing options for its cell and gene therapy manufacturing business, WuXi Advanced Therapies (WuXi ATU).
In a statement, WuXi AppTec said it has not entered into any binding deals regarding the operations of WuXi ATU and acknowledged uncertainty as to whether it will eventually decide to dispose of the business or explore other options to retain and continue its operations.
The announcement has raised concerns among investors about the future prospects and potential restructuring or divestment of the WuXi ATU business, which specializes in cell and gene therapy manufacturing. Analysts have expressed mixed views on the impact of this move on WuXi AppTec's overall operations and profitability.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.